Abstract: Process for the preparation of the compound consisting of the peptide chain: leucyl -- seryl -- arginyl -- leucyl -- phenylalanyl -- aspartyl -- asparaginyl -- alanine (I), characterized in that the synthesis is carried out from constituent amino-acids of the peptide chain (I), or from peptide elements resulting from the condensation of two or several of these basic amino-acids, and by the condensation of these amino-acids or peptide elements, in a succession of steps so that the basic amino-acids occur in the final peptide chain in the order indicated in (I).

Abstract: An initial solution of crude urokinase especially of human origin, is subjected to exclusion chromatography by contact with a DEAE cellulose resin, following adjustment of the pH of the solution to a value of from 4 to 6, and of its conductivity to a value of from 15,000 to 25,000 micromhos. An effluent enriched in urokinase is collected. A urokinase, mixed with foreign proteins, especially pyrogens, is purified by a partial saturation of an aqueous solution of this mixture by ammonium sulphate to a value for which the precipitate formed would not entrain more than 5% of the total activity of urokinase of the initial solution. A supernatant liquid enriched in urokinase is collected . A complex of urokinase and heparin, urokinase heparinate, is made by reacting an enriched solution of urokinase with a solution of heparin. It has relative activities of 30,000 to 100,000 CTA units of urokinase for 100 Iu of heparin.

Abstract: Novel salts of papaverine are constituted by the thienyl-carboxylates of papaverine notably papaverine thienyl-2-carboxylate. A papaverine thienyl-carboxylate is prepared by reacting papaverine base with the corresponding thiophene carboxylic acid. The medicaments comprise, as active principle, a papaverine thienyl-carboxylate associated with a solid excipient making it suitable for administration by the oral route, or with an excipient making it suitable for administration by the rectal route. The medicament, is useful for the treatment of hyperspasmodicity of the smooth muscles, and for the treatment of vascular disorders, notably due to senescence, more particularly those bringing into action cortical reactivity.

Abstract: An insoluble, solid matrix carrying simultaneously several different enzymatic functions, is constituted by the conjoint association by irreversible binding on a previously activated matrix support, of a nuclease selected from the group of ribonucleases A, T.sub.1, T.sub.2, U.sub.2 and an alkaline phosphatease. Free activated groups of the matrix after binding of the enzymes, are neutralized by a free amino organic base. The support is selected from among non-denaturing supports effecting the irreversible physical adsorption of the enzymes, such as supports of glass or quartz beads, highly cross-linked gels of the agarose or cellulose type. Polymers A.sub.n U.sub.OH, A.sub.n C.sub.OH, A.sub.n G.sub.OH and/or oligonucleotides U, C, A or G, of predetermined lengths, can be obtained by fractionating the polyribonucleotides by incubation with the insoluble solid matrix.

Abstract: The present invention relates to pharmaceutical compositions of stable urokinase-heparin complexes, wherein the urokinase is purified, and methods for use thereof.

Abstract: Process for obtaining cultures of tumoral cells in vitro, of specifically human origin.The cultures of tumoral cells in vitro are prepared, particularly from human tumoral cells obtained from surgical samples of malignant tumors, by introducing, into the culture system, an anti-human lymphocyte serum described in the U. S. patent application Ser. No. 440,726, filed Feb. 8, 1974, which neutralizes the cytocidic and macrophagic activities of the lymphoblastoid and of the activated monocyte cells, present in the cellular system, with respect to the tumoral cells, thus permitting the establishment of continuous lines of tumoral cells in vitro.Utilization of the continuous lines of tumoral cells in vitro thus obtained as means of elucidating the cancer process in man and as means of ascertaining the activity of new cancerostatic and cancerolytic medicaments.

Abstract: A pharmaceutical composition for the treatment of disorders in the formation or regeneration of the cutaneous connective tissue including disorders due to aging of the skin, which composition comprises a homogeneous mixture of vitamin B.sub.12 in an amount effective for the above treatment and a carrier vehicle therefor. The carrier vehicle is a fatty skin cream of a pH between about 4 and 7 which is non-oxidizing and non-reducing and is pharmaceutically acceptable for repeated applications to the skin over prolonged periods of time.

Abstract: The derivatives have the general formula ##STR1## in which X is a hydrogen atom or a methyl, phenyl or benzyl group; Y is a carbon chain comprising 2 to 6 carbon atoms, saturated or unsaturated, unsubstituted or substituted by alkyl, alkoxyl or halogen groups, said chain including if necessary, instead and in place of an aliphatic link, a carbonyl or alcohol group; Z is constituted by a hydrogen atom or defines at least an alkyl, alkoxyl or halogen group fixed at any position of the quinolinyl nucleus. They have high anti-inflammatory and analgesic activities.

Abstract: A process for preparing the calcium or magnesium salt of N-acetyl-amino-6-hexanoic acid which comprises reacting directly acetyl-caprolactame with calcium or magnesium hydroxide within an aqueous solution.

Abstract: A drug having an anti-agglutinating effect on platelets and a hypocoagulating effect formed of an association of papaverine or a physiologically acceptable salt thereof with a thiosulphate of a physiologically acceptable metal.